Gene
MCL1
MCL1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (24), Actionable biomarkers (1), Trial mentions (11), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention MCL1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 18 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 30 of 11,460 | 0.26% |
| 2022 | 1 of 8,285 | 0.01% | 27 of 13,598 | 0.20% |
| 2021 | 1 of 8,692 | 0.01% | 41 of 15,045 | 0.27% |
| 2020 | 3 of 7,640 | 0.04% | 19 of 14,459 | 0.13% |
| 2019 | 1 of 7,300 | 0.01% | 26 of 12,159 | 0.21% |
| 2018 | 1 of 6,927 | 0.01% | 27 of 11,854 | 0.23% |
| 2017 | 0 of 6,558 | 0.00% | 28 of 11,595 | 0.24% |
Showing 10 of 37 years.
Assay-provider ledger (24)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Illumina | Unclassified | Clinical validationAnalytical validation | 2 | May 13, 2025 |
| NEW ENGLAND BioLabs | Reagent supplier | Clinical validation | 1 | May 13, 2025 |
| QIAGEN | Reagent supplier | Clinical validation | 1 | May 13, 2025 |
| Affymetrix | Reagent supplier | Analytical validation | 1 | November 01, 2015 |
| Agilent Technologies | Reagent supplier | Clinical validationAnalytical validation | 2 | November 01, 2015 |
Showing 5 of 24 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| MCL1 amplification | Tubulin Inhibitors | responsive | No disease recorded | Cancer Genome Interpreter |
Trial mentions (11)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05107856 | Trial eligibility (AACT) |
| NCT02656849 | Trial eligibility (AACT) |
| NCT04807881 | Trial eligibility (AACT) |
| NCT05834244 | Trial eligibility (AACT) |
| NCT04543305 | Trial eligibility (AACT) |
Showing 5 of 11 trial mentions.
Target-disease associations (337)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| 25-hydroxyvitamin D3 measurement | measurement | GWAS credible sets |
| AL amyloidosis | cardiovascular disease | Literature (Europe PMC) |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
Showing 5 of 337 associations.
Vendor sourcing (28)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | MCL1 | View trial NCT01828476 |
| AbbVie Inc. | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Prior exposure to any targeted myeloid cell leukemia-1 (MCL-1) inhibitor. * Antineoplastic therapy (including any cytotoxic, targeted and/or investigati... | View trial NCT04178902 |
| AbbVie Inc. | Trial sponsor | Mentioned in trial textTrial free-text mention | MCL1 | View trial NCT04178902 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.307C>T (p.R103C) alteration is located in exon 1 (coding exon 1) of the MCL1 gene. This alteration results from a C to T substitution at nucleotide pos... | View ClinVar record SCV003528823.2 |
| Bayer (Germany) | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Patients must have advanced cancer for which no curative therapy exists and have a malignancy which matches one of the following cohorts: * MCL1 ampl... | View trial NCT02656849 |
Showing 5 of 28 sourcing records.
Trial-cited literature (375)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety Analysis. | Cancer prevention research (Philadelphia, Pa.) | 2026 | 0 |
| Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia. | Blood | 2025 | 9 |
| A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies. | Blood advances | 2025 | 9 |
| Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | 6 |
| Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia. | Cancer research communications | 2025 | 4 |
Showing 5 of 375 papers.
Protein variant mentions (5)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.K194A | 1 | 2023 | PMID 37880389 |
| p.K197A | 1 | 2023 | PMID 37880389 |
| p.M306* | 1 | 2018 | PMID 29681510 |
| p.R201A | 1 | 2023 | PMID 37880389 |
| p.R310K | 1 | 2019 | PMID 31792461 |
Literature-extracted relations (49)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| METFORMIN | Chemical | positive_correlate |
Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety Analysis. | 2026 |
| Homoharringtonine | Chemical | negative_correlate |
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1. | 2025 |
| Homoharringtonine | Chemical | negative_correlate |
Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis. | 2024 |
| Busulfan | Chemical | positive_correlate |
ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells. | 2022 |
| Homoharringtonine | Chemical | negative_correlate |
The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia. | 2021 |
Showing 5 of 49 relation assertions.
Organizations publishing (368)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The University of Texas System | Academic | 40 | 2006 to 2025 |
| Dana-Farber Cancer Institute | Other | 30 | 2005 to 2025 |
| Mayo Clinic | Hospital | 17 | 2010 to 2025 |
| Harvard Medical School | Academic | 14 | 2009 to 2022 |
| Mass General Brigham | Hospital | 10 | 2014 to 2023 |
Showing 5 of 368 organizations.
Where MCL1 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- respiratory or thoracic disease
- urinary system disease
328 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.